Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : Biib save search
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE
Published: 2023-01-10 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.14%
H: 1.23%
C: 1.13%
treatment europe lecanemab disease alzheimer's application authorization
Biosimilars market size to increase by USD 42,227.12 million: Europe to contribute 46% of market growth - Technavio
Published: 2022-12-08 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.55%
H: 0.39%
C: 0.39%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 0.82%
C: -1.64%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.32%
C: -0.93%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.46%
H: 0.59%
C: -2.22%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.0%
H: 1.34%
C: -1.29%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.48%
H: 0.35%
C: -1.95%
europe growth market
Alkermes plc Reports First Quarter 2022 Financial Results
Published: 2022-04-27 (Crawled : 14:20) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.3%
H: 1.11%
C: -0.33%
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.67%
H: 4.05%
C: 3.38%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 13.01%
H: 2.29%
C: -0.95%
results
Update on Regulatory Submission for Aducanumab in the European UnionBiogen to seek re-examination following CHMP negative opinion for aducanumab
Published: 2021-12-17 (Crawled : 13:30) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: 0.0%
europe chmp negative submission
Update on Regulatory Submission for Aducanumab in the European Union
Published: 2021-12-17 (Crawled : 12:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: 0.0%
europe submission
Update on Regulatory Review of Aducanumab in the European Union
Published: 2021-11-17 (Crawled : 13:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -5.12%
H: 2.69%
C: 1.5%
europe
The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis
Published: 2021-11-16 (Crawled : 14:30) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
multiple sclerosis treatment europe sclerosis granted
Loulou Foundation Announces Launch of Pre-Competitive Industry Collaboration for CDKL5 Deficiency Disorder Observational Study
Published: 2021-10-25 (Crawled : 14:15) - biospace.com/
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.18%
H: 3.13%
C: 2.06%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.45%
H: 2.07%
C: 1.48%
collaboration
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
Published: 2021-10-04 (Crawled : 11:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 0.56%
H: 1.86%
C: -1.33%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.04%
H: 1.11%
C: -1.11%
europe
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
Published: 2021-09-17 (Crawled : 14:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
multiple sclerosis treatment europe sclerosis approval chmp
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
Published: 2021-09-06 (Crawled : 15:00) - globenewswire.com
FWP | $1.95 7.74% 7.18%
|
Health Technology
| Email alert
Add to watchlist
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
| Email alert
Add to watchlist
europe patent
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.